Disc Medicine (IRON) Other financing activities (2020 - 2026)
Disc Medicine (IRON) posted quarterly Other financing activities of $2.4 million for Q2 2026, up 164.13% year-over-year from $892000.0 in Q2 2025, and up 133.27% quarter-over-quarter from $1.0 million in Q1 2026.
Disc Medicine (IRON) Other financing activities (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Other financing activities for 7 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other financing activities rose 164.13% year-over-year to $2.4 million; the TTM figure through Jun 2026 stood at $10.5 million (up 243.32% YoY), while the FY2025 annual figure was $8.6 million, up 190.36% from the prior year.
- Other financing activities advanced to $2.4 million in Q2 2026 per IRON's latest filing, from $1.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $5.6 million in Q4 2025 and bottomed at $22000.0 in Q3 2022.
- Historically, Other financing activities has averaged $995777.8 across 5 years, with a median of $712000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other financing activities slumped 99.97% — and 2023, when it soared 2709.09%.
- Disc Medicine's Other financing activities stood at $56000.0 in 2022, then soared by 1339.29% to $806000.0 in 2023, then surged by 49.13% to $1.2 million in 2024, then jumped by 369.47% to $5.6 million in 2025, then plunged by 58.25% to $2.4 million in 2026.
- Business Quant data shows IRON's Other financing activities at $2.4 million in Q2 2026, $1.0 million in Q1 2026, and $5.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Disc Medicine | 3.02 Bn | 3.02 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.36 Mn |
| Jun 30, 2026 | 2.36 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Sep 30, 2025 | -889,000.00 |
| Sep 30, 2025 | -889,000.00 |
| Jun 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.18 Mn |
| Mar 31, 2025 | 287,000.00 |
| Mar 31, 2025 | 287,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 401,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Mar 31, 2024 | 806,000.00 |
| Mar 31, 2024 | 806,000.00 |
| Dec 31, 2023 | -1.92 Mn |
| Dec 31, 2023 | -1.92 Mn |